Clinical Trial Update: Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating NB-001 for recurrent herpes labialis. The study reports on safety, pharmacokinetics, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Labialis

Drugs mentioned

• NB-001

Snippet

Sponsor: NanoBio Corporation | Conditions: Herpes Labialis | Phase 2 | Status: COMPLETED